Blog

  • Scientists Use Climate Data To Map, Predict Amphibian Chytrid Disease

    Scientists Use Climate Data To Map, Predict Amphibian Chytrid Disease

    Researchers may have a new tool in the fight to protect neotropical frogs from extinction, thanks to climate data. In a recently published study in the journal Diversity and Distributions, researchers from the Smithsonian’s National Zoo and Conservation Biology Institute (NZCBI) and the Smithsonian Tropical Research Institute (STRI) created a high-resolution map of Panama showing how a deadly amphibian disease moved across Panama over a 13-year period. But the data also provides insight into where the disease is the most dangerous and shows regions that may be havens for reintroduced, captive-bred frogs. 

    Since its first scientific description in 2000, Batrachochytrium dendrobatidis (Bd), a fungus that causes the deadly amphibian chytrid disease, has devastated amphibian populations in Central and South America. Believed to have originated in Asia, chytrid has since spread to many parts of the world, and the disease is responsible for wiping out nine frog species in Panama alone. 

    Like other fungi, chytrid requires a cool, wet environment to thrive. In chytrid-friendly conditions, disease outbreaks can decimate frog populations. But scientists have found that the fungus cannot thrive when the temperature is too high or the air is too dry. While the disease has spread throughout mainland Panama, the team wondered if the climate parameters might create an opportunity to find pockets where chytrid was less likely to kill. 

    By pairing satellite data with 13 years’ worth of atmospheric modeling, researchers created an ultra-high-resolution, daily temperature and humidity map for the nation. They paired this with a second dataset of over 4,900 disease samples taken from 314 sites across Panama. The second dataset tracked the amount of fungus present on each frog, known as the fungal load, over 13 years. When overlaid, the two data sets provided a clear picture of when and where the chytrid disease was the most intense. Higher elevations consistently remained more hospitable to the fungus, but rainy seasons brought chytrid-friendly conditions to the lowlands and led to waves of outbreaks. 

    “By compiling the hard-earned data from many amphibian researchers, we have been able to draw an unprecedented, detailed picture of the intensity of Bd in Panama through time and space,” said Carrie Lewis, doctoral student at George Mason University’s Department of Geography and Geoinformation Science, who led the study. “My hope is that we can use this detailed information to inform conservation actions in a more refined way.” 

    Although chytrid disease has devastated amphibian populations, the presence of the chytrid fungus alone is not a death sentence. Recognizing this, the research team built three models: one showing fungal presence; a second at “medium intensity,” which researchers consider an indicator of a serious infection; and a third at “high intensity,” which researchers associated with significant disease outbreaks. Researchers found that by examining the weather conditions 15 days prior to sampling, they could predict the presence and intensity of the chytrid fungus. 

    By mapping out the path and intensity of chytrid, it became clear that the disease thrives in mountainous regions, which tend to remain cooler and more humid than lowland areas. With this knowledge, researchers may be able to identify climatic refuges—areas less suitable for the chytrid disease where frogs may have a fighting chance against the fungus. 

    “The ability to identify places where frogs might be able to survive chytrid is critical for two reasons,” said Brian Gratwicke, NZCBI biologist and senior author of the study. “One, it allows us to look for frogs in those areas who might have developed resistance to the fungus. Two, those same areas might be sites where we can return captive-bred frogs into the wild. Both aspects could be significant turning points in the fight against the chytrid disease.” 

    Since 2009, the Panama Amphibian Rescue and Conservation Project based in Gamboa, Panama, has bred 12 species of frogs, all of which are facing extinction. After years of successful breeding, there are now enough animals to begin rewilding efforts. As researchers work toward reintroduction trials for imperiled Panamanian species, these prediction models will be crucial to determining when and where trials should take place. 

    This collaboration between 18 coauthors was partially supported with funding from the National Science Foundation, the German Science Foundation and the Bezos Earth Fund through the Tropical Amphibian Research Initiative.  

    Smithsonian’s National Zoo and Conservation Biology Institute (NZCBI)
    NZCBI leads the Smithsonian’s global effort to save species, better understand ecosystems and train future generations of conservationists. Its two campuses are home to more than 2,200 animals, including some of the world’s most critically endangered species. Always free of charge, the Zoo’s 163-acre park in the heart of Washington, D.C., features animals representing 400 species and is a popular destination for children and families. At the Conservation Biology Institute’s 3,200-acre campus in Virginia, breeding and veterinary research on nearly 250 animals representing 20 species provide critical data for the management of animals in human care and valuable insights for conservation of wild populations. NZCBI’s 305 staff and scientists work in Washington, D.C., Virginia and with partners at field sites across the United States and in more than 30 countries to save wildlife, collaborate with communities and conserve native habitats. NZCBI is a long-standing accredited member of the Association of Zoos and Aquariums.

    Smithsonian Tropical Research Institute (STRI)
    Headquartered in Panama City, Panama, STRI is a unit of the Smithsonian Institution. Our mission is to understand tropical biodiversity and its importance to human welfare, to train students to conduct research in the tropics and promote conservation by increasing public awareness of the beauty and importance of tropical ecosystems. Visit the institute at our website and on Facebook, X and Instagram for updates.

    # # #

    SI-173-2025


    Continue Reading

  • Cristiano Ronaldo spends £270k on gifts for Georgina Rodriguez after engagement is confirmed

    Cristiano Ronaldo spends £270k on gifts for Georgina Rodriguez after engagement is confirmed

    • Ronaldo spends £270K on engagement presents
    • Popped the question earlier this week
    • Gifts include car and watch

    Follow GOAL on WhatsApp! 🟢📱

    Continue Reading

  • M4 Ultra Mac Pro rumor processor codenamed hidra

    M4 Ultra Mac Pro rumor processor codenamed hidra

    New code accidentally leaked by Apple suggests it is still hard at work on a new Mac Pro powered by the M4 Ultra chip.

    Apple’s premium desktop machine is currently powered by the aging M2 Ultra chip with a 24-core CPU and a 60-core GPU. That’s backed up by a 32-core Neural Engine.

    Now, code discovered by Macworld hints at the possible arrival of a new M4 Ultra version of the machine. If accurate, this could be the first Mac to use an M4 Ultra chip.

    The new Mac Pro has an internal identifier of t8152. It also matches the previously known Hidra codename.

    Apple’s Mac Pro isn’t updated very frequently. The M4 Ultra chip would replace the M2 Ultra version of the Mac Pro that is on sale as of August 14, 2025.

    While we don’t know for sure what the M4 Ultra will have in terms of core counts, it’s likely to sport 32 CPU cores and an 80-core GPU. That’s assuming, as expected, that it’s based on the silicon already available in the M4 Max MacBook Pro and M4 Max Mac Studio.

    While this code leak does suggest that Apple is still tinkering with an M4 Ultra-powered Mac Pro, it doesn’t mean it will ever see the light of day. Apple tests tons of devices, there are frequently code snippets left behind, and not all of the leaked devices find their way into an Apple Store.

    That being said, there is little doubt that the Mac Pro is overdue for an update. The current model debuted in 2023, and it seems unlikely Apple would skip both the M3 and M4 families of chips without refreshing its towered Mac.

    The wildcard here is the M5 chips, likely to be released in the fall of 2025. M5 chip identifiers recently appeared in iOS 18 code, so it’s likely that Apple’s next-gen chips aren’t all that far from release.

    Continue Reading

  • Franco Mastantuono’s Surprising Real Madrid Shirt Number Confirmed

    Franco Mastantuono’s Surprising Real Madrid Shirt Number Confirmed

    Real Madrid confirmed Franco Mastantuono will inherit Gonzalo García’s No. 30 shirt, the same number the Argentine donned at River Plate.

    Despite signing with Los Blancos back in June, Mastantuono had to wait until his 18th birthday to be officially presented at Real Madrid City. The forward started his time off in the Spanish capital with a medical and then gave his first remarks as a Real Madrid player before revealing his new shirt.

    Although Mastantuono was expected to take the number 25, which is the last first-team squad number available ahead of the 2025–26 season, the teenager instead claimed 30.

    Leaving the number 25 open gives Real Madrid the opportunity to sign one more player during the summer transfer window to round out their first-team squad. The club has been in the market for a midfield reinforcement, most recently linked with Manchester City’s Rodri and Crystal Palace’s Adam Wharton.

    The decision also means Mastantuono is technically registered as a Real Madrid Castilla player. Real Madrid took a similar approach when Vinícius Júnior and Rodrygo joined the team as teenagers.

    The good news for Real Madrid is that they can still have Mastantuono with the first team all season long. Since the Argentine is under 23 years old, La Liga regulations allow the new signing to feature for the first team without needing a number change, even if he crosses the 10-match threshold that usually demands a player take a number no higher than 25.

    The scenario benefits all parties involved, especially since Mastantuono already has ties to the number 30.

    “It was me who asked president Florentino [Pérez] to take number 30,” he said. “It’s a special number for me. I wore it at River Plate too.

    “It’s a very special day for me. It’s a dream come true as a footballer and as a person, to join a club like Real Madrid, the biggest in the world. I’m thrilled, and I want to share that joy with you because this will be a day I will remember forever.

    “I promise I will give my life to this jersey, it’s the dream I have always had.”

    READ THE LATEST REAL MADRID NEWS, TRANSFER RUMORS AND MORE


    Continue Reading

  • FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

    FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

    Metastatic Castration-Resistant Prostate Cancer |

    Image credit: © pikovit – stock.adobe.com

    The FDA has granted fast track designation to HLD-0915 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).1

    HLD-0915 is currently under investigation in a first-in-human, phase 1/2 trial (NCT06800313) in patients with mCRPC. The open-label, multi-center trial is designed to ascertain the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of HLD-0915 monotherapy in patients with mCRPC.

    The study’s phase 1 dose escalation will explore the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion of HLD-0915 as a single agent. Subsequent phase 2 expansion cohorts will further characterize the safety and efficacy of HLD-0915.

    “We are pleased HLD-0915 has been granted fast track designation by the FDA for patients with mCRPC,” Christian Schade, president and chief executive officer of Halda Therapeutics, stated in a news release. “Fast track designation is an important step forward as we work to advance this program through clinical development and, ultimately, to bring a novel, highly selective, oral-based treatment option to patients living with this challenging disease.”

    HLD-0915 is an orally administered, bifunctional small molecule therapy designed to selectively target prostate cancer tumor cells by binding the androgen receptor and effector proteins. The ternary complex stimulates the formation of new protein-protein interactions, preventing an essential function within cancer cells that translates antitumor activity.

    In preclinical prostate cancer models, treatment with HLD-0915 led to tumor shrinkage and reductions in prostate-specific antigen (PSA), with favorable therapeutic index, including in drug-resistant models.

    The ongoing phase 1/2 trial will seek to further define the therapeutic profile of the agent. Eligible patients must be at least 18 years of age and have received a histological, pathological, and/or cytological diagnosis of prostate adenocarcinoma.2 Additional eligibility criteria stipulate that patients must have undergone prior orchiectomy and/or ongoing androgen deprivation therapy and have a castrate level of serum testosterone.

    Progression on prior therapy, defined by PSA progression with or without radiographic progression, is also mandated. Traditional enrollment criteria, including an ECOG performance status of 0 or 1, life expectancy of at least 3 months, and adequate hematological, renal, and hepatic function, are also required. Notably, patients must have the ability to swallow an oral medication, given HLD-0915’s administration. Patients who are receiving a stable dose of bisphosphonate or denosumab for 30 days prior to enrollment are included.

    Patients whose tumors express a neuroendocrine or small cell carcinoma component on histopathology will be excluded. Patients will also be prohibited from accrual if they have experienced a recent major bleed or have a known bleeding disorder, are receiving continuous corticosteroids at a prednisone-equivalent dose of greater than 10 mg/day, or have received systemic anticancer therapy or other investigational drugs within 2 weeks before the first dose of HLD-0915.

    Approximately 33 patients will receive HLD-0915 in 21-day treatment cycles until evidence of disease progression or study discontinuation.

    The primary objective of phase 1 is to establish the frequency of dose-limiting toxicities and adverse effects. Secondary objectives of phase 1 include the evaluation of PK parameters, the proportion of patients with PSA declines measuring at least 30%, 50%, and 90%, and clinical end points like objective response rate, duration of response, radiographic progression-free survival, and time to response.

    In February 2025, Halda Therapeutics announced that the first patient had been dosed in the trial.3

    “We are very pleased to have initiated the clinical evaluation of HLD-0915 to address the unmet needs of cancer patients with mCRPC,” Schade stated at the time of the announcement. “Initiation of this study marks a significant step in advancing our novel small molecule RIPTAC [Regulated Induced Proximity TArgeting Chimeras] modality as an important new approach for the treatment of cancer.”

    References

    1. Halda Therapeutics receives FDA fast track designation for HLD-0915 for the treatment of metastatic castration-resistant prostate cancer. News release. Halda Therapeutics. August 14, 2025. Accessed August 14, 2025. https://haldatx.com/halda-therapeutics-receives-fda-fast-track-designation-for-hld-0915-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer/
    2. A study of HLD-0915 in patients with metastatic castration resistant prostate cancer (mCRPC). ClinicalTrials.gov. Updated April 16, 2025. Accessed August 14, 2025. https://clinicaltrials.gov/study/NCT06800313
    3. Halda Therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating HLD-0915 in metastatic castration-resistant prostate cancer. News release. Halda Therapeutics. February 24, 2025. Accessed August 14, 2025. https://haldatx.com/halda-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-hld-0915-in-metastatic-castration-resistant-prostate-cancer/

    Continue Reading

  • Taylor Swift, Travis Kelce share rare kiss on New Heights podcast

    Taylor Swift, Travis Kelce share rare kiss on New Heights podcast

    Taylor Swift made headlines with a rare, unfiltered interview on New Heights, the podcast hosted by her boyfriend, Travis Kelce, and his brother Jason Kelce. Over the two-hour episode, Swift not only revealed details about her much-anticipated 12th studio album The Life of a Showgirl but also shared personal stories about her romance with Kansas City Chiefs tight end. The couple ended the interview with a light-hearted, on-air kiss: much to Jason’s amusement. According to E! Online, reacting to the moment, Jason exclaimed, “Oh my gosh, alright.” After which, the singer was seen getting shy.

    Taylor Swift and Travis Kelce on the New Heights podcast.(YouTube/New Heights)

    How the podcast sparked a romance between Taylor Swift and Travis Kelce

    On the latest episode of the podcast, Swift credited the New Heights for bringing her together with Travis after he had famously mentioned making her a friendship bracelet and wanting to meet her during the Eras Tour, in a 2023 episode.

    Swift, recalling the moment, said that her relatives insisted she meet Travis. She added, “It felt like something out of an 80s John Hughes movie…and it worked.” She called Kelce ‘the good kind of crazy’ and a ‘human exclamation point.’

    New Album: Life Behind the Curtain

    The podcast was not all about romance; Swift also announced the release date of her next album, The Life of a Showgirl. The album, created during her record-breaking Eras Tour, will be coming out on October 3. She said the album reflected everything that goes on behind the curtain of her public life. The cover art, featuring Swift in a bejewelled gown submerged in water, symbolises her quiet post-performance moments.

    During the podcast, Swift said that she has been wanting to make an album like this for a very long time. The album, she said, is an upbeat, joyful, and wildly dramatic: a stark contrast to her previous album, The Tortured Poets Department. Pre-orders for the album crashed her website moments after the reveal.

    Also read: ‘She’s been cooking’: First glimpses from Taylor Swift’s The Life of a Showgirl has the internet melting

    Easter eggs, album rights, and personal triumphs

    Swift talked about her unique ‘Easter eggs’ and noted they never reference her personal life properly, only her art, reported BBC. However, she did reminisce about her emotional triumph, stating that she was able to reclaim her first six albums and described it as a life-altering moment.

    Love, football and sourdough bread

    The couple shared light-hearted anecdotes of their life together, baking sourdough (complete with a few accidental cat hairs and a hint of Travis’ chest hair) and Swift’s rudimentary understanding of football. Travis complimented Swift for immersing herself into his world, whereas she noted that she appreciated his patience and how he led her along.

    FAQs:

    Q: When will Taylor Swift’s new album be released?

    A: The Life of a Showgirl will be released on October 3.

    Q: How did Taylor Swift and Travis Kelce meet?

    A: Their connection began after Travis mentioned her on New Heights, sparking mutual interest and encouragement from friends and family.

    Q: What makes this album different from her last?

    A: Swift describes it as upbeat, joyful, and dramatic, in contrast to the introspective tone of The Tortured Poets Department.

    Q: What are Easter eggs in Swift’s work?

    A: Secret references or clues hidden in her music, videos, and performances for fans to decode.

    Continue Reading

  • Clues From the Microbes Inside Us – HDBuzz

    Clues From the Microbes Inside Us – HDBuzz

    While Huntington’s disease (HD) primarily affects the brain, the genetic change that causes the disease is present in every cell throughout the body. Because of that, it has influences beyond the brain, including in the gut. Increasing evidence suggests that changes in gut microbes, leaky barriers, inflammation, and nerve signaling may contribute to HD progression. A recent review of published research maps the “gut–brain superhighway” in HD, highlighting where traffic flows smoothly, where it’s blocked, and where detours might offer new treatment options.

    How Human Are You, Really?

    If someone were to ask you what species you see when you look in the mirror, you would undoubtedly say human. But people are actually made up of more microbes than anything else. Shockingly, there are more microbial cells in your body than human cells. And 99% of the genetic material in your body is from microbes – only 1% of your DNA is of human origin! So it makes sense that when we think about human biology, we should seriously consider the role that microbes play in our health.

    Microbes are microscopic organisms, like bacteria, viruses, fungus, or yeast. When we think of such things, we typically think of infections, but most microbes are harmless, and even helpful. The various microbes that live in our gut help us digest various foods, aid with nutrient absorption, and work to develop our immune systems. Increasing evidence also suggests that the gut, and the microbes that live there, can impact brain health. 

    The gut is so closely tied to the brain that some scientists call it the “second brain”. This is because there is an extensive network of neurons within our gut that directly communicates with the brain through the vagus nerve. The vagus nerve is the main connection that controls the parasympathetic nervous system. Think of your parasympathetic nervous system as controlling “rest and digest” functions. It helps to regulate digestion, heart rate, and our immune system. 

    From the Brain to the Belly: Why the Gut Matters in HD

    We tend to picture HD as a one-way street, where the gene that causes HD produces a faulty protein that causes a decline in brain health. But it’s more like a two-way superhighway with lots of back and forth between the brain and the rest of the body, especially between the brain and the gut, referred to as the “gut-brain axis”. 

    This road is busy with traffic lanes like the vagus nerve, immune cells, and the “second brain” of the gut. There are vehicles carrying chemical messengers made by gut microbes and border checkpoints such as the gut lining and the blood–brain barrier, which should only let safe travelers through.

    In HD, problems at almost every point on this route can slow traffic, let dangerous cargo through, or disrupt communication entirely.

    When we think of bacteria and viruses, we typically jump to infections, but most microbes are actually helpful! In our gut, they aid in food digestion, nutrient absorption, and even help boost our immune system. However, people with Huntington’s disease might have changes to their microbial makeup that could contribute to disease progression. 

    Roadwork and Weak Bridges: Barriers Breaking Down

    HD’s faulty protein, expanded huntingtin (HTT), isn’t just in the brain, it’s everywhere, including the gut. This widespread presence may contribute to why people with HD often have symptoms in parts of their bodies beyond the brain, including gastrointestinal problems like chronic diarrhea, constipation, incontinence, and poor nutrient absorption.

    Two major “bridges” on our superhighway are affected – the gut barrier and the blood-brain barrier. The gut barrier can become “leaky,” letting microbes or their components escape into the bloodstream. There is some evidence for this in people with the gene for HD before and after they start to show symptoms, seemingly at levels comparable to those in inflammatory bowel disease. 

    The blood–brain barrier also shows signs of “loosened bolts” in HD, with fewer tight junction proteins holding it together. When both bridges are compromised, harmful substances from the gut could have a clearer route to the brain. Supporting this possibility, traces of bacterial and fungal DNA have been found in the brains of people with HD after death. While contamination is possible, it suggests that microbes, or at least parts of microbes, might be able to cross compromised barriers of the gut and brain.

    Traffic Jams: Inflammation Along the Route

    The gut is the body’s largest immune organ. In HD, this immune system seems stuck in overdrive, like a traffic jam of inflammatory signals. Cytokines, which play a role in regulating the immune response and inflammation, seem to be present at increased levels in blood from people with HD, years before symptoms start. Adding to that, higher levels of some cytokines appear to be linked with worse symptoms and lower scores that chart someone’s ability to carry out day-to-day tasks. 

    But encouragingly, it seems that some beneficial gut bacteria may be able to dampen this inflammation, acting like traffic police to keep things moving. However more work is needed to understand the exact type of bacteria that could provide a benefit and if we could harness this as a future treatment option for people with HD. 

    Inflammation is also seen inside the gut itself, with high levels of a biomarker that signals stress on the gut lining. 

    Faulty Signaling: Vagus Nerve Disruptions

    The vagus nerve is the main fiber-optic cable of the gut–brain superhighway. It carries both sensory updates from the gut to the brain and calming “anti-inflammatory” signals back down. In HD, low vagal tone, a sign of reduced nerve activity, seems to be present even 20 years before motor symptoms. 

    Low tone could worsen inflammation and has been linked to depression, a common symptom of HD. Researchers are asking whether stimulating the vagus nerve could one day be a therapeutic on-ramp.

    The Microbial Passenger List: Who’s in the Vehicles?

    Studies are suggesting that the gut microbiome in HD has a different passenger list than in healthy individuals. Diversity may be lower, meaning fewer types of microbes, and certain species might be missing or reduced. Less diversity in the gut microbiome has been linked to lower immune function, poorer digestion, and fatigue.

    While more work is needed, researchers are starting to tease apart the microbial differences in the gut of people with HD. For example, the presence of certain microbes may be linked to better thinking skills but worse motor symptoms. And there appears to be sex-specific differences in both humans and mice, suggesting men and women may have different microbes present. 

    Possible Road Repairs: Interventions in the Works

    If the gut–brain superhighway in HD has traffic jams and potholes, the big question is, can we fix it? Scientists are exploring various ideas to get traffic flowing more smoothly. One option is probiotics (adding “good” bacteria) or prebiotics (feeding the good bacteria already there). These are generally safe, but the first HD trial testing probiotics didn’t show big changes in gut health or thinking skills, so more work is needed in this area to know if this might be beneficial. It might be that we need longer treatment or different combinations of probiotics are needed to see an effect.

    Food itself could be a powerful repair tool. In HD mouse models, a high-fiber diet seemed to boost thinking skills, lift mood, and improve gut health. But the most striking findings from this study compared a high-fiber diet to a no-fiber diet in mice, which isn’t realistic for people, who are more likely to consume a low-fiber diet by comparison. So more work would be needed to test this theory.

    In people, following a Mediterranean-style diet that is rich in fruits, vegetables, whole grains, and healthy fats has been reported by some to improve quality of life and perhaps allow for fewer movement problems. Other diets, like the ketogenic (very low-carb, high-fat) approach or intermittent fasting, have shown mixed results and come with serious risks. It’s a reminder that there’s probably no one-size-fits-all diet for HD.

    The “gut-brain axis” is the link between our gut and our brain, where chemical messengers are sent on a molecular superhighway. Huntington’s disease can cause changes that alter traffic patterns, sending messengers through barriers they shouldn’t cross, causing inflammation, and potentially contributing to worsening of disease symptoms. 

    It’s not just about food, how we live also shapes the gut–brain connection. In HD mice, physical activity and a stimulating environment seem to delay disease onset and slow progression, while also changing the gut microbiome. Even certain antibiotics, if chosen carefully, have shown reduced inflammation and protected nerve cells in lab models. But broad-spectrum antibiotics, the kind that wipe out a wide range of bacteria, can cause long-term damage to gut diversity, so they’re not a realistic option for intervening with the microbiome.

    An Overlooked Exit: Oral Health

    After the gut, the mouth has the second largest microbial population within the body. While the effect of HD on the microbes in the mouth hasn’t been studied, we do know that as HD progresses, it can become harder to keep up with oral hygiene. This can lead to gum disease, cavities, and inflammation in the mouth.

    That might sound like a small problem compared to the challenges of HD, but oral health affects the whole body. Inflammation from the mouth can spill over into the bloodstream, adding to the overall “traffic jam” of inflammation we already see in HD. Over time, this could make gut and brain problems worse.

    The good news is that this is an area where we already have easy tools. Regular dental care, help with brushing and flossing, and even specially designed oral probiotics could all help keep the mouth’s microbial community balanced. These simple steps might not just improve comfort and quality of life, they could also help reduce inflammation that feeds into HD’s wider effects.

    It’s a reminder that in a complex condition like HD, the most effective “road repairs” might come from surprising places. From the microbes in our gut to the health of our mouth, every stop along the gut–brain superhighway could hold clues, and opportunities, for improving life with HD.

    Summary

    • The gut–brain axis is a busy two-way superhighway of nerves, immune cells, and chemical messengers.
    • In HD, barriers leak, inflammation surges, and microbial balance shifts, potentially influencing disease progression.
    • Early studies suggest diet, probiotics, or exercise could one day help, but more research is needed.
    • Oral health may be an underexplored but important off-ramp in managing HD’s systemic inflammation.

    Learn More

    Original research article, “The microbiota–gut–brain axis in Huntington’s disease: pathogenic mechanisms and therapeutic targets” (open access).

    Continue Reading

  • Horse racing trainer Bill Turner, Brocklesby Stakes specialist, dies aged 78 after fall | Horse racing

    Horse racing trainer Bill Turner, Brocklesby Stakes specialist, dies aged 78 after fall | Horse racing

    The trainer Bill Turner has died aged 78 after having a serious accidenton Monday. Turner, who was based in Sigwells in Somerset, was a former jockey and as a trainer became synonymous with the Brocklesby Stakes at Doncaster, having won the traditional first race of the Flat turf season six times.

    He had been in a serious condition in hospital after reportedly fracturing his skull in a fall and his daughter, Kathy, announced his death on Thursday afternoon. Speaking at Chepstow racecourse, she told Sky Sports Racing: “Dad passed away about an hour and a half ago.

    “We got the call in the lorry, I’d made the decision to come here. the horse [Red Snapper] was to run in dad’s name in his honour. Whatever had happened he would have wanted that.

    “He slipped away this morning. The support from everyone in racing has been absolutely outstanding. I’ve tried to reply to as many people as I could, but I am so sorry if I haven’t replied to you or someone else. The love that man had was absolute.

    “He wasn’t just my dad and my sister’s dad and Ryan’s grandfather, he was everyone’s dad and the people who he has helped in their careers saw him as a dad. He would have preferred to have been going flat out up the gallops but unfortunately it was a freak accident.

    “I still can’t get round that this injury has done this to him, as I’ve pulled him out from such serious injuries on the gallops. Only last Sunday he was refelting my sister’s salon roof.”

    Bill Turner (right) with the jockey Gina Mangan (left) and his daughter Kathy after Umming N’ Ahing won at Nottingham in April 2023. Photograph: Steven Cargill/racingfotos.com/Shutterstock

    Mick’s Yer Man was Turner’s last Brocklesby winner in 2013 and that victory held special significance. Kathy Turner added: “His best ever moment was when Ryan [While, his grandson] won the Brocklesby on Mick’s Yer Man .”

    Brant Dunshea, the British Horseracing Authority’s chief executive, said: “Everybody at the BHA is deeply saddened by the news of Bill Turner’s death. My thoughts, along with my colleagues at the BHA and everyone involved in the sport, are with Bill’s family and friends, as well as everyone who works at the yard.

    “Bill was a wonderful stalwart of our sport. He poured his heart and soul into racing, both as a jockey and then a trainer, and we will particularly miss his annual runner in the Brocklesby Stakes, which he won an impressive six times.

    “We will do everything we can to support the yard during this incredibly challenging period.”

    Continue Reading

  • Iqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal is one of the most famous and non controversial social media celebrities, known for her family vlogging YouTube channel Sistrology. She made her channel in 2020 and got a huge success in it. Iqra’s subscribers kept on increasing and she never looked back. She also handles controversial situations intelligently by not responding to them. Currently, she has 5.57 million subscribers on YouTube. Her sisters and parents are also equally popular because of digital creation. Iqra Kanwal is married to Areeb Pervaiz and they are conceiving their first child. Iqra keeps her fans updated about her daily life through vlogs and fans love her daily routine, her sisters and parents.

    Iqra Kanwal Shares Azadi Special Family Photoshoot

    Today, the gorgeous digital media influencer uploaded her stunning Azadi Special family photoshoot. Iqra Kanwal was glowing in a beautiful white peplum style shirt which was paired with a dark green dupatta and white trouser, the pregnancy glow was visible on her face. The other family members were also twinning in white and green. Here we have gathered Iqra’s family pictures for you:

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Iqra Kanwal Shares Azadi Special Family PhotoshootIqra Kanwal Shares Azadi Special Family Photoshoot

    Continue Reading

  • Deescalating Postoperative Radioiodine in Low-Risk Thyroid Cancer

    Deescalating Postoperative Radioiodine in Low-Risk Thyroid Cancer

    Microscopic photorealistic image of thyroid cancer cells – Generated with Google Gemini AI

    New data from the IoN trial, a landmark phase 3 randomized study, provides compelling evidence that postoperative radioiodine ablation can be safely omitted for a substantial portion of patients with low-risk differentiated thyroid cancer.1,2 The findings, published in The Lancet, mark a significant step toward deescalating therapy and reducing patient burden for this common malignancy.

    Study Rationale and Design

    While radioiodine ablation has long been a standard component of postoperative care for many patients with thyroid cancer, its necessity has been increasingly questioned, particularly for those with a low risk of recurrence. The IoN study, a multicenter, noninferiority trial conducted across the United Kingdom, was designed to directly address this clinical uncertainty.

    Researchers enrolled 504 patients with low-risk differentiated thyroid cancer, defined as those with pT1 or pT2 tumors and no evidence of nodal involvement (N0 or Nx). Patients were randomized 1:1 to receive ablation or no ablation. The study’s primary objective was to determine if avoiding radioiodine ablation was noninferior to receiving it, as measured by the 5-year recurrence-free rate.

    The trial’s noninferiority design is critical for clinical practice, as it sought to prove that a less aggressive approach was no worse than the current standard. This is a powerful statistical framework for evaluating deescalation strategies.

    Key Findings and Clinical Implications

    5-year recurrence-free rates

    With a median follow-up of 6.8 years (IQR, 5.6–8.6) in the no ablation group and 6.6 years (IQR, 4.8–8.5), there were 8 recurrences in the no ablation group vs 9 in the ablation group. These corresponded to 5-year recurrence-free rates of 97.9% (95% CI, 96.1%–99.7%) and 96.9% (range, 94.7%–99.1%), respectively. Recurrence rates were higher in patients with pT3 or pT3a tumors, with 9% (n = 4/46) of overall patients with pT3 or pT3a tumors experiencing a recurrence vs 3% (n = 13/458) in patients with pT1 or pT2 tumors.

    Adverse events (AEs) were similar between arms, with the most common AE being fatigue (25% in the no ablation group vs 28% in the ablation group), lethargy (14% vs 14%), and dry mouth (10% vs 9%). Further, there were no treatment-related deaths.

    This is a notable development for the seventh most common cancer type globally, as it means patients can be spared the side effects associated with radioiodine, which can include salivary gland damage, dry mouth, and an increased risk of secondary malignancies. Furthermore, avoiding ablation eliminates the need for hospitalization and the logistical complexities of managing a radioactive substance, which can be a significant psychological and financial burden for patients.

    These findings build upon a growing body of evidence. Previous trials like ESTIMABL1 and HiLo demonstrated that a lower dose of radioiodine was noninferior to a higher dose. The ESTIMABL2 trial further suggested that ablation could be avoided in certain patients. The IoN study expands on this by including patients with pT2 tumors, providing a broader evidence base that supports a more conservative, risk-stratified approach to postoperative management.

    The trial was not powered for subgroup analysis, and therefore, clinical judgment and established guidelines should still be followed for these higher-risk groups.

    “Studies are ongoing to refine the risk of N1 disease, and until they are published, clinicians should continue their current practice for treating pT3, pT3a, and N1a disease,” study authors noted. “Some clinicians will prefer to still offer ablation to these patients, but in some circumstances—for example, if patients with N1a disease have low or undetectable thyroglobulin concentrations and no adverse tumour features—not giving ablation could be considered along with close monitoring.”

    REFERENCES:
    1. Mallick U, Newbold K, Beasley M, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial. Lancet. 2025 Jul 5;406(10498):52-62. doi: 10.1016/S0140-6736(25)00629-4. Epub 2025 Jun 18.
    2. Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer. ESMO. August 12, 2025. Accessed August 14, 2025. https://tinyurl.com/mr29fed2

    Continue Reading